Source:http://linkedlifedata.com/resource/pubmed/id/16322269
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
23
|
pubmed:dateCreated |
2005-12-2
|
pubmed:abstractText |
The activator protein-2alpha (AP-2) transcription factor plays a key role in regulating expression of genes involved in tumor growth and metastasis of human melanoma. We sought to assess the prognostic significance of AP-2 expression and its role in the transition of nevi to metastatic melanoma. Two cohorts were analyzed. One was a "progression" microarray containing melanoma specimens from M.D. Anderson Cancer Center representing 84 cases and the other was a retrospective cohort from Yale University representing 214 primary melanomas and 293 metastases. Analysis of total AP-2 expression using two quantitative systems [automated quantitative analysis (AQUA) and laser scanning cytometry (LSC)] revealed no correlation with diagnosis group. LSC analysis of the M.D. Anderson Cancer Center array showed that the number of cells expressing nuclear AP-2 was highest in the benign nevi group (11.85%) and significantly decreased in each phase of melanoma progression to 0.39% in the metastatic group. Both LSC and AQUA showed decreased nuclear AP-2 levels and increased cytoplasmic AP-2 that is directly proportional to progression. Neither nuclear nor cytoplasmic expression levels correlated with outcome. Intriguingly, the ratio of cytoplasmic to nuclear AP-2 predicted outcome in the entire population and in the primary tumors alone, demonstrating the power of the ratio to normalize for variations. Furthermore, the AP-2 ratio directly correlated with other clinicopathologic factors, including Breslow depth (R = 0.334, P < 0.001). We show that a high level of AP-2 expression in the cytoplasm relative to the nucleus correlates with poor prognosis and the loss of nuclear AP-2 expression is associated with malignant transformation and progression of melanoma.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA16672,
http://linkedlifedata.com/resource/pubmed/grant/CA76098,
http://linkedlifedata.com/resource/pubmed/grant/GM07205,
http://linkedlifedata.com/resource/pubmed/grant/P50CA093459,
http://linkedlifedata.com/resource/pubmed/grant/R21 CA100825,
http://linkedlifedata.com/resource/pubmed/grant/R33 CA106709
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
11185-92
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:16322269-Cell Nucleus,
pubmed-meshheading:16322269-Cytoplasm,
pubmed-meshheading:16322269-Fluorescent Antibody Technique,
pubmed-meshheading:16322269-Humans,
pubmed-meshheading:16322269-Melanoma,
pubmed-meshheading:16322269-Predictive Value of Tests,
pubmed-meshheading:16322269-Prognosis,
pubmed-meshheading:16322269-Protein Array Analysis,
pubmed-meshheading:16322269-Transcription Factor AP-2
|
pubmed:year |
2005
|
pubmed:articleTitle |
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.
|
pubmed:affiliation |
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|